Filing Flows › Companies › Regeneron Pharmaceuticals › Timeline
Regeneron Pharmaceuticals stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+40.6% to $904.35
Regeneron Pharmaceuticals (REGN) stock rose 41% over the last 252 sessions, to $904.35. On the way it reported 4 quarters, its insiders filed 2 open-market trades and 16 Form 144 notices of planned sales, and the company filed 2 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 4, 2026 | Form 144 | Form 144: Jason Pitofsky plans to sell $175K | −4.5% (−6.1% vs SPY) | — | — |
| Nov 4, 2026 | Form 144 | Form 144: Jason Pitofsky plans to sell $3.8M | −4.5% (−6.1% vs SPY) | — | — |
| Nov 4, 2026 | Insider sale | Pitofsky Jason sold $412K | −4.5% (−6.1% vs SPY) | — | — |
| Nov 3, 2026 | Form 144 | Form 144: Huda Zoghbi plans to sell $7.2M | +1.3% (+1.0% vs SPY) | — | — |
| Nov 3, 2026 | Insider sale | Zoghbi Huda Y sold $6.7M | +1.3% (+1.0% vs SPY) | — | — |
| Nov 2, 2026 | Form 144 | Form 144: George L. Sing plans to sell $20.4M | +3.5% (+4.0% vs SPY) | −2.6% (+0.2% vs SPY) | — |
| Nov 2, 2026 | Form 144 | Form 144: Christine Poon plans to sell $7.5M | +3.5% (+4.0% vs SPY) | −2.6% (+0.2% vs SPY) | — |
| Nov 2, 2026 | Form 144 | Form 144: Joseph LaRosa plans to sell $4.3M | +3.5% (+4.0% vs SPY) | −2.6% (+0.2% vs SPY) | — |
| Oct 30, 2026 | Earnings | Earnings: beat the EPS estimate by 23.5% | +12.5% (+14.3% vs SPY) | +9.8% (+14.6% vs SPY) | — |
| Oct 30, 2026 | Form 144 | Form 144: Michael S Brown plans to sell $1.6M | +12.5% (+14.3% vs SPY) | +9.8% (+14.6% vs SPY) | — |
| Oct 30, 2026 | Form 144 | Form 144: Marion McCourt plans to sell $984K | +12.5% (+14.3% vs SPY) | +9.8% (+14.6% vs SPY) | — |
| Oct 30, 2026 | Form 144 | Form 144: Kathryn Guarini plans to sell $360K | +12.5% (+14.3% vs SPY) | +9.8% (+14.6% vs SPY) | — |
| Oct 14, 2026 | Form 144 | Form 144: Andrew J Murphy plans to sell $3.2M | +3.3% (+4.4% vs SPY) | +7.0% (+8.1% vs SPY) | — |
| Oct 6, 2026 | 8-K | Material definitive agreement | +1.7% (+1.1% vs SPY) | +4.9% (+4.5% vs SPY) | +29.3% (+31.9% vs SPY) |
| Sep 30, 2026 | 8-K | Directors and officers: departures, appointments, pay | −3.1% (−3.3% vs SPY) | −2.1% (−4.0% vs SPY) | +7.7% (+6.8% vs SPY) |
| Sep 3, 2026 | Form 144 | Form 144: Marion McCourt plans to sell $969K | −1.0% (−2.1% vs SPY) | −7.1% (−6.2% vs SPY) | −14.7% (−15.6% vs SPY) |
| Sep 2, 2026 | Form 144 | Form 144: Kathryn Guarini plans to sell $340K | +3.4% (+2.9% vs SPY) | −2.0% (−2.1% vs SPY) | −11.4% (−11.9% vs SPY) |
| Sep 2, 2026 | Form 144 | Form 144: Marion McCourt plans to sell $1.0M | +3.4% (+2.9% vs SPY) | −2.0% (−2.1% vs SPY) | −11.4% (−11.9% vs SPY) |
| Aug 10, 2026 | Form 144 | Form 144: Kathryn Guarini plans to sell $320K | +3.0% (+3.0% vs SPY) | +2.4% (+2.0% vs SPY) | +3.4% (+4.3% vs SPY) |
| Aug 10, 2026 | Form 144 | Form 144: Huda Y Zoghbi plans to sell $640K | +3.0% (+3.0% vs SPY) | +2.4% (+2.0% vs SPY) | +3.4% (+4.3% vs SPY) |
| Jul 30, 2026 | Earnings | Earnings: beat the EPS estimate by 40.0% | +6.0% (+4.3% vs SPY) | +10.0% (+4.6% vs SPY) | +15.1% (+9.5% vs SPY) |
| Jul 2, 2026 | Form 144 | Form 144: Arthur F. Ryan plans to sell $250K | +4.6% (+4.7% vs SPY) | +6.7% (+5.9% vs SPY) | +20.0% (+19.8% vs SPY) |
| Apr 29, 2026 | Earnings | Earnings: beat the EPS estimate by 6.4% | −6.4% (−6.4% vs SPY) | −4.1% (−5.8% vs SPY) | −16.2% (−22.0% vs SPY) |
| Jan 30, 2026 | Earnings | Earnings: beat the EPS estimate by 6.4% | −1.1% (−0.8% vs SPY) | +2.3% (+4.7% vs SPY) | +5.5% (+6.6% vs SPY) |
Insiders’ record here
In the year on the chart, Regeneron Pharmaceuticals' insiders reported 0 open-market buys ($0) and 2 sales ($7.1M).
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Regeneron Pharmaceuticals: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.